ES2163295T3 - Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. - Google Patents

Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.

Info

Publication number
ES2163295T3
ES2163295T3 ES98947694T ES98947694T ES2163295T3 ES 2163295 T3 ES2163295 T3 ES 2163295T3 ES 98947694 T ES98947694 T ES 98947694T ES 98947694 T ES98947694 T ES 98947694T ES 2163295 T3 ES2163295 T3 ES 2163295T3
Authority
ES
Spain
Prior art keywords
formula
phenyl
heteroaryl
transferasa
farnesil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98947694T
Other languages
English (en)
Inventor
Jean-Claude Arnould
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2163295T3 publication Critical patent/ES2163295T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un compuesto de fórmula (1) Ar1C(R12)R13 OAr2(CH2)p-Ar 3 Fórmula (1) en la cual Ar1 representa: R5 es hidrógeno, alquilo C1-4, fenil-alquilo C1-4, R6 es hidrógeno, alquilo C1-4, hidroxi-alquilo C1-4, halo-alquilo C1-4, dihalo-alquilo C1-4, alcoxiC1-4, alcoxi C1-4 -alquilo C1-4, sulfanil-alquilo C1-4, amino-alquilo C1-4, N-(alquil C1-4)amino-alquilo C1-4, N,N-di(alquil C1-4)amino-alquilo C1-4 o fenil-alquilo C1-4; mes0,1ó 2; R12 y R13 son independientemente hidrógeno o alquilo C1-4; Ar 2 es fenilo o heteroarilo; p es0ó 1; Ar 3 es fenilo, piridinilo, piridazinilo, pirimidilo o pirazinilo, estando sustituido el anillo en los átomos de carbono del anillo por R2 y -(CH2)nR3 y en lacualAr 3 está unido a Ar 1 C(R12)R13 CH(AR2)O por un átomo de carbono del anillo; R2 es un grupo de la fórmula (2): **fórmula** en la cual R7 es hidrógeno o alquilo C1-4, R8 es -(CH2)q-R10 en cuya fórmulaq es 0-4 y R10 es alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, hidroxi, alcoxi C1-4, carbamoílo, N-alquil C1-4carbamoílo, N,N-(dialquil C1-4)carbamoílo, alquilo C1-4, fenilo, tienilo, o alcanoil -amino C1-4, R9 es hidroxi, alcoxi C1-6, cicloalquiloxi C3-9, heterociclil-oxi, heterociclil-alcoxi C1-4 o -NH-SO2-R11 en cuya fórmula R 11 representa trifluorometilo, alquilo C1-4, fenilo, heteroarilo, aril-alquilo C1-4 o heteroarilalquilo C1-4; o R2 representa una lactona de fórmula (3) Fórmula (3) teniendo el grupo de fórmula (2) o (3) conguración L o Den el carbono quiral alfa del aminoácido libre correspondiente; n es0,1ó 2; R 3 es fenilo o heteroarilo; los anillos fenilo y heteroarilo en R3,R5,R6,R9,R11 y Ar2 están sustituidos opcionalmente de manera independiente en los átomos de carbono del anillo con hasta tres sustituyentes seleccionados de alquilo C1-4, halógeno, hidroxi, alcoxi C1-4, alcoxiC1-4-carbonilo, alcanoílo C1-4, alcanoiloxi C1-4, amino, alquilamino C1-4, di(alquil C1-4)-amino, alcanoilamino C1-4, nitro, ciano, carboxi, tiol, alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alcano C1-4-sulfonamido, N-(alquilsulfonil C1-4)-N-alquilamino C1-4, aminosulfonilo, N-(alquil C1-4)-amino-sulfonilo, N,N-di(alquil C1-4)aminosulfonilo, carbamoílo, N-(alquil C1-4)carbamoílo, N,N-(di-alquil C1-4)-carbamoílo, carbamoil-alquilo C1-4, N-(alquil C1-4)carbamoil-alquilo C1-4, N,N-(di-alquil C1-4)carbamoil-alquilo C1-4, hidroxi-alquilo C1-4 y alcoxiC1-4alquilo C1-4, y en los grupos NH del anillo (que reemplazan hidrógeno) con alquilo C1-4, alcanoílo C1-4, alquilsulfonilo C1-4, halo-alquilo C1-4, difluorometilo o trifluorometilo; o una(o) de sus sales, profármacos o solvatos farmacéuticamente aceptables.
ES98947694T 1997-10-22 1998-10-19 Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. Expired - Lifetime ES2163295T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97402505 1997-10-22
EP97402502 1997-10-22

Publications (1)

Publication Number Publication Date
ES2163295T3 true ES2163295T3 (es) 2002-01-16

Family

ID=26147905

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98947694T Expired - Lifetime ES2163295T3 (es) 1997-10-22 1998-10-19 Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.

Country Status (10)

Country Link
US (3) US6342765B1 (es)
EP (1) EP1025088B1 (es)
JP (1) JP2001524455A (es)
AT (1) ATE205195T1 (es)
AU (1) AU9453098A (es)
DE (1) DE69801590T2 (es)
DK (1) DK1025088T3 (es)
ES (1) ES2163295T3 (es)
PT (1) PT1025088E (es)
WO (1) WO1999020611A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1140858A2 (en) 1998-12-23 2001-10-10 AstraZeneca AB Arylpropenylimidazoles as farnesyl-protein transferase inhibitors
WO2001014314A1 (en) * 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Benzene derivatives having aromatic substituents and processes for the preparation thereof
GB9930317D0 (en) 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
US6271418B1 (en) 2000-02-22 2001-08-07 Nippon Kayaku Co., Ltd. Process for preparing (hetero) aromatic substituted benzene derivatives
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
EP2215246B1 (en) 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
CN105764526B (zh) 2013-08-26 2020-12-15 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
US4221803A (en) * 1979-05-09 1980-09-09 Recordati, S.A. Substituted dibenzyl ethers and pharmaceutical compositions containing said ethers for the treatment of infections
FI803127L (fi) 1979-10-03 1981-04-04 Glaxo Group Ltd Heterocykliska foereningar
US4518607A (en) * 1983-07-18 1985-05-21 Syntex (U.S.A.) Inc. Male oral contraceptive N-alkylimidazole derivatives, compositions, and method of use therefor
US5298655A (en) 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
US5238922A (en) 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5340828A (en) 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5352705A (en) 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5326773A (en) 1992-10-29 1994-07-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2185441A1 (en) 1994-03-15 1995-09-21 Michael D. Lewis Isoprenyl transferase inhibitors
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
US5478934A (en) 1994-11-23 1995-12-26 Yuan; Jun Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
JPH11503419A (ja) * 1995-03-29 1999-03-26 メルク エンド カンパニー インコーポレーテッド ファルネシル−タンパク質トランスフェラーゼ阻害剤
US5534537A (en) * 1995-03-29 1996-07-09 Merck & Co., Inc. Prodrugs of inhibitors of farnesyl-protein transferase
US5710171A (en) 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
ATE236632T1 (de) 1995-11-06 2003-04-15 Univ Pittsburgh Inhibitoren der protein-isoprenyl-transferase
WO1998032741A1 (en) 1997-01-29 1998-07-30 Zeneca Limited Inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
ATE205195T1 (de) 2001-09-15
DE69801590T2 (de) 2002-07-11
US20020058665A1 (en) 2002-05-16
US20020052376A1 (en) 2002-05-02
DK1025088T3 (da) 2001-11-12
JP2001524455A (ja) 2001-12-04
US6342765B1 (en) 2002-01-29
EP1025088A1 (en) 2000-08-09
DE69801590D1 (de) 2001-10-11
EP1025088B1 (en) 2001-09-05
WO1999020611A1 (en) 1999-04-29
AU9453098A (en) 1999-05-10
PT1025088E (pt) 2002-01-30

Similar Documents

Publication Publication Date Title
DE69801590D1 (de) Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
BRPI9608082A (pt) derivado de quinazolina, sal de cloridreto do mesmo, e, composição farmacêutica
BR0010520A (pt) Novos compostos farmaceuticamente ativos
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
MY129540A (en) Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
NO913750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
DK1326613T3 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
YU87990A (sh) Postupak za dobijanje novih bis-(1h-indol-3-il)-maleinimid derivata
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
ATE287397T1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
HUP9901969A2 (hu) N-(merkapto-alkanoil)-cisztein-származékok alkalmazása ischemia kezelésére szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1025088

Country of ref document: ES